[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glanzmann-thrombasthenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glanzmann-thrombasthenia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,83,110,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100371709","videomicroscopy-for-the-prediction-of-bleeding-in-constitutional-haemorrhagic-diseases-100371709",false,"NCT04119908","Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases","Interest of Sublingual Videomicroscopy for the Prediction of Bleeding in Von Willebrand Disease and Other Constitutional Haemorrhagic Diseases","VIDEO-BLEED","Inclusion Criteria:\n\n* Adult patient with a significant form of von Willebrand disease (according to the inclusion criteria of the Willebrand Disease French Reference Center), a Glanzmann Thrombasthenia, a moderate to severe Haemophilia A or a woman carrying the hemophilia gene\n* Social insured patient\n\nExclusion Criteria:\n\n* Minor patient\n* Refusal of consent\n* Person benefiting from a system of legal protection\n* Pregnant patient","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","In Willebrand disease, there is currently no test available to identify non-invasively patients with a high risk of bleeding from angiodysplasias The study propose to use a sublingual capillary bed analysis by video-microscopy, a sensitive, reproducible and non-invasive technique, to assess whether sublingual capillary density is predictive of hemorrhagic risk for patients with von Willebrand disease.",[27,28],"Von Willebrand Diseases","Glanzmann Thrombasthenia",[30,31,32,33],"constitutional haemorrhagic diseases, Videomicroscopy, prediction, bleeding","Videomicroscopy","prediction","bleeding","RECRUITING","2026-05-19",{"date":37,"type":38},"2026-05-20","ACTUAL",{"date":40,"type":38},"2023-05-24",{"date":42,"type":21},"2028-05-24",{"name":44,"class":45},"University Hospital, Lille","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":46},"100579147","athndataset-registry-100579147","NCT06820515","ATHNdataset Registry","American Thrombosis and Hemostasis Network ATHNdataset Registry","Inclusion Criteria:\n\n* Any participant evaluated for or the potential to have a blood disorder who has an encounter with an ATHN Affiliate.\n* Participants of any age.\n* Participant is able to provide consent or assent; a Legally Authorized Representative (LAR) may provide consent on a participant's behalf if a participant is unable to provide self-consent\n\nExclusion Criteria:\n\n* Any participant unable to provide consent or assent to participate in the ATHNdataset",{"count":55,"type":21},200000,"OBSERVATIONAL","The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems.\n\nDoctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.",[59,60,61,62,63,28,64,65,27],"Hemophilia","Thrombosis","Hemophilia A","Hemophilia B","Sickle Cell Disease","Bleeding Disorder","Blood Disorder",[67,68,69,70,71,72],"bleed event","bleed treatments","adverse events","joint bleed","bleeding disorder","bleeding symptoms","2026-04-16",{"date":75,"type":38},"2026-04-21",{"date":77,"type":38},"2024-10-25",{"date":79,"type":21},"2055-10-31",{"name":81,"class":82},"American Thrombosis and Hemostasis Network","NETWORK",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":46},"100603464","phase-2-eptacog-beta-in-glanzmanns-hetlfb-strength-studyfid531-100603464","NCT07136857","Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)","Study To Assess Response to Eptacog Beta iN Patients With Glanzmann THromboasthenia (STRENGTH )","STRENGTH","Inclusion Criteria:\n\n* Adult or Pediatric persons with inherited Glanzmann thrombasthenia (see diagnostic criteria below)\n* Severe bleeding phenotype\n* Adequate hepatic function\n* Adequate renal function\n* Adults subject (≥18 years of age) or caregiver (parent or legally authorized representative) for minor subjects, subjects with cognitive impairment, or subjects with impaired decision-making capacity have provided written informed consent, and the participant has given consent\u002Fassent (if applicable)\n* Ability to speak, read, and understand the English language\n\nExclusion Criteria:\n\n* Thrombocytopenia (platelet count \\\u003C 100k)\n* Acquired Glanzmann thrombasthenia secondary to autoimmune disease, malignancy, or medication\n* Inherited or acquired bleeding diathesis other than Glanzmann thrombasthenia\n* Have a history of venous or arterial thrombotic event within 2 years of study enrollment\n* Active malignancy\n* Known or suspected hypersensitivity to rabbits, rabbit protein, other forms of rFVIIa, or to any of the EB excipients\n* Have received an investigational drug within 30 days or within 5 half-lives of that investigational drug (whichever is longer) or are expected to receive such a drug during participation in this study\n* Be using aspirin, non-steroidal anti-inflammatory drugs (NSAIDS), herbs, natural medications, or other drugs with platelet inhibitor properties for the duration of the study\n* Be using or administered anticoagulant agents for the duration of the study\n* Have any life-threatening disease or other disease or condition which, according to the investigator's judgement, could imply a potential hazard to the patient, or interfere with the study participation or study outcome\n* Use of systemic immunomodulators at enrollment or planned use during the study",{"count":92,"type":21},6,[94],"PHASE2","This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder. Eptacog beta (EB) is not currently approved by the U.S. Food and Drug Administration (FDA) for this condition.\n\nThe study will assess the effectiveness and safety of eptacog beta (EB) when used to treat serious bleeding events, and in an optional phase, when used routinely to prevent bleeding. During the first three (3) months, participants will manage any bleeding episodes with their standard treatment (e.g., factor products or platelet transfusions). After this initial period, they will use the study drug to treat serious bleeding events.\n\nParticipants will have approximately 4 to 5 visits with their hematologist over the 9-month study period. They will also be asked to complete a diary documenting bleeding episodes and treatments, and to answer questions about how bleeding affects their daily life. Blood samples will be collected to monitor their condition and any potential side effects of the study drug.\n\nAt the end of the main study, participants will have the option to enter an optional extension phase, where they will receive routine intravenous infusions of the study drug 2 to 3 times per week for 6 months to help prevent future bleeding episodes and complications.",[28],[98,99,100],"Severe Bleeding","Prevention of Bleeding","Eptacog beta (EB)","2025-11-24",{"date":103,"type":38},"2025-12-01",{"date":105,"type":38},"2025-10-02",{"date":107,"type":21},"2026-12",{"name":109,"class":45},"Emory University",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":117,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100074964","the-genetics-and-functional-basis-of-inherited-platelet-white-blood-cell-red-blood-cell-and-blood-clotting-disorders-100074964","NCT00230165","The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.","Studies of Interactions Among Normal and Abnormal Blood Cells, and the Vessel Wall, and Studies of Genetic and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell and Coagulation Disorders","Inclusion Criteria:\n\nA. Normal Healthy Volunteers:\n\n1. Normal healthy volunteers\n2. 18 years of age or older\n3. Either sex\n4. Any ethnic background.\n\nB. Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and\u002For quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation (including von Willebrand disease):\n\n1. Adults and children\n2. Either sex\n3. Any ethnic background\n\nExclusion Criteria:\n\nA. Normal Healthy Volunteers:\n\n1. For studies of platelets that may be affected by anti-platelet therapy, ingestion of aspirin or similar medication in the past week.\n2. Having given blood in the last 8 weeks such that the current donation would exceed a total of 250 ml for the 8 week period.\n3. Having given blood in the past week such that this donation would result in more than 2 donations in one week.\n\nB. Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and\u002For quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation (including von Willebrand disease).\n\n1. For studies of platelets that may be affected by antiplatelet therapy, ingestion of aspirin or similar medication in the past week\n2. If the patient is known to have a hematocrit ≥25 (assay performed in past 3 months), the same blood drawing criteria as in A, with the addition that for children less than 18 years of age, the maximum amount of blood allowed to be donated in an 8 week period is the lesser of 50 ml or 3 ml\u002Fkg.\n3. If the patient has a hematocrit \\\u003C25 or if the hematocrit is unknown, the blood drawing limit is the lesser of 20 ml or 1 ml\u002Fkg in any 8 week period.",true,{"count":119,"type":21},60,"Blood contains red blood cells, white blood cells, and platelets, as well as a fluid portion termed plasma. We primarily study blood platelets, but sometimes we also analyze the blood of patients with red blood cell disorders (such as sickle cell disease), white blood cell disorders, and disorders of the blood clotting factors found in plasma.\n\nBlood platelets are small cell fragments that help people stop bleeding after blood vessels are damaged. Some individuals have abnormalities in their blood platelets that result in them not functioning properly. One such disorder is Glanzmann thrombasthenia. Most such patients have a bleeding disorder characterized by nosebleeds, gum bleeding, easy bruising (black and blue marks), heavy menstrual periods in women, and excessive bleeding after surgery or trauma. Our laboratory performs advanced tests of platelet function and platelet biochemistry. If we find evidence that a genetic disorder may be responsible, we analyze the genetic material (DNA and RNA) from the volunteer, and when possible, close family members to identify the precise defect.",[28],[123,124,125,126,60],"Platelets","Erythrocytes","Leukocytes","Coagulation","2025-10-15",{"date":129,"type":38},"2025-10-20",{"date":131,"type":4},"2005-09",{"date":133,"type":21},"2030-06",{"name":135,"class":45},"Rockefeller University",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":144,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100531764","multinational-glanzmann-study-100531764","NCT06204042","Multinational Glanzmann Study","Glanzmann Thrombasthenia Natural History Study+","Glanzmann-NHS","Inclusion Criteria:\n\n* Adult patients (≥16 years);\n* Biochemically or genetically diagnosed Glanzmann thrombasthenia.\n* Willing and able to give written informed consent.\n\nExclusion Criteria:\n\n* Patients with acquired thrombasthenic states caused by auto-immune disorders or drugs.","16 Years",{"count":146,"type":21},200,"Glanzmann thrombasthenia is a rare autosomal recessive platelet disorder characterized by a lack of functional integrins alfaIIb or beta3 (glycoproteins IIb\u002FIIIa). The prevalence is variously reported to be between 1:200,000 to 1:1,000,000, with substantial geographic variation. The clinical phenotype is dominated by an increased mucocutaneous bleeding tendency. In absence of a primary bleeding prophylaxis, the current treatment of Glanzmann thrombasthenia is mainly focused on prevention or management of bleeding. However, as potential new therapies emerge, clinicians require unbiased, long-term safety and efficacy data for both current treatment and new therapies.\n\nWe have designed this study to investigate genetic phenotype (ITGA2B and ITGB3 genes) and the prevalence of antibodies against human leucocyte antigen (HLA) and human platelet antigen (HPA), the latter two being a potential consequence of the current golden standard treatment: platelet transfusion. The results of this study will be merged with a longitudinal registry with retrospective and prospective data collection of clinical phenotype, haemorrhagic burden and bleeding management. Analysis of the data from the Glanzmann-NHS+ study and the registry will help us to get a better understanding of the clinical variation among participants with Glanzmann thrombasthenia. The ultimate goal is to accelerate improvement in the care of patients with Glanzmann thrombasthenia.",[28],"NOT_YET_RECRUITING","2024-02-26",{"date":152,"type":38},"2024-02-28",{"date":154,"type":21},"2024-03-01",{"date":156,"type":21},"2029-03-01",{"name":158,"class":45},"UMC Utrecht"]